Guggenheim analyst Brad Canino initiated coverage of Kura Oncology (KURA) with a Neutral rating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Optimistic Buy Rating for Kura Oncology: KO-2806’s Potential in ccRCC and Market Opportunities
- Kura Oncology’s KO-2806: A Promising Investment with $1.5 Billion Market Potential in RCC
- Kura Oncology’s Earnings Call: Progress Amidst Challenges
- Kura Oncology price target lowered to $24 from $28 at Citizens JMP
- Kura Oncology price target lowered to $27 from $29 at BofA